NYMC Faculty Publications
Update on Pharmacologic Therapy for Pulmonary Embolism
Author Type(s)
Faculty
DOI
10.1177/1074248413506612
Journal Title
Journal of Cardiovascular Pharmacology and Therapeutics
First Page
159
Last Page
169
Document Type
Article
Publication Date
3-1-2014
Department
Pharmacology
Keywords
Animals, Anticoagulants, Aspirin, Fibrinolytic Agents, Heparin, Low-Molecular-Weight, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Pulmonary Embolism, Warfarin
Disciplines
Medicine and Health Sciences
Abstract
Warfarin, unfractionated heparin (UFH), and low-molecular-weight heparins are anticoagulants that have been used for treatment of pulmonary embolism. Currently approved drugs for treatment of venous thromboembolism include UFH, enoxaparin, dalteparin, fondaparinux, warfarin, and rivaroxaban. The advent of newer oral anticoagulants such as rivaroxaban, dabigatran, and apixaban has provided us with alternative therapeutic options for long-term anticoagulation. This article will give an overview of the various anticoagulant drugs, use in various clinical scenarios, data supporting their clinical use, and recommendations regarding duration of anticoagulant therapy.
Recommended Citation
Harikrishnan, P., Palaniswamy, C., & Aronow, W. S. (2014). Update on Pharmacologic Therapy for Pulmonary Embolism. Journal of Cardiovascular Pharmacology and Therapeutics, 19 (2), 159-169. https://doi.org/10.1177/1074248413506612
